Considering the 2018 outbreak of yellow fever in Brazil, the Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos/Fiocruz) is optimizing the production and capacity processes of vaccines against the disease. There is also an initiative to develop inactivated batches, with the goal of running clinical trials to study restrictions of use of the vaccine in pregnant women and people with immunodeficiencies.

In Brazil, the vaccine has been produced by the Oswaldo Cruz Foundation (Fiocruz) since 1937, and is considered one of the most effective ever produced. Up to August 2018, Bio-Manguinhos had delivered more than 15 million doses to the National Vaccination Program (PNI) and exported to countries in South America and Africa.